[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000.
Hokland
Peter
P
Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk
Nyvold
Charlotte Guldborg
CG
Stentoft
Jesper
J
Ommen
Hans Beier
HB
Ebbesen
Lene Hyldahl
LH
Braendstrup
Karin
K
Andersen
Bodil Lind
BL
Mikkelsen
Lone Siig
LS
Ostergaard
Mette
M
D014408:Biomarkers, Tumor / Q000032:analysis; D006801:Humans; D007938:Leukemia / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics; D016133:Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor